ARCHIVES

Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

Senate Investigates Opioid Manufacturers, Requests Study of Impact of DEA Policies

May 11, 2012

Soviet Exchanges Rise And Fall With Politics

August 23, 1991

NCI Begins Latin American Cancer Research Network

April 10, 2009

L-PAM Benefit To Post-Menopausal Patients Challenged

October 29, 1976

In Brief: John Kovach Succeeds Moertel As Mayo CC Head; DEA Deputy Appointed; New NCAB Member Named

February 7, 1986

Tobacco Industry Walkout Unlikely To Imperil Legislation

April 17, 1998